Results 71 to 80 of about 56,171 (221)

GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia.

PLoS ONE, 2016
Based on animal and ex-vivo experiments, Growth/Differentiation Factor-15 (GDF15, also called Macrophage Inhibitory Cytokine-1, MIC1), a member of the transforming growth factor-beta family, and Matrix Metalloproteinase-9 (MMP9), a member of the matrix ...
Walter Maetzler, Willy Deleersnijder, Valérie Hanssens, Alice Bernard, Kathrin Brockmann, Justus Marquetand, Isabel Wurster, Tim W Rattay, Lorenzo Roncoroni, Eva Schaeffer, Stefanie Lerche, Anja Apel, Christian Deuschle, Daniela Berg   +13 more
doaj   +1 more source

The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen [PDF]

, 2011
Increased brain α-synuclein (SNCA) protein expression resulting from gene duplication and triplication can cause a familial form of Parkinson's disease (PD).
Bandyopadhyay, Sanghamitra, Cahill, Catherine M., Castelvetri, Ippolita Cantuti, Greig, Nigel H., Huang, Xudong, Lahiri, Debomoy K., Maccecchini, Maria L., Mikkilineni, Sohan, Rogers, Jack T., Smith, Deborah H.   +9 more
core   +1 more source

Motor and Cognitive Outcome After Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease Harboring GBA1 Variant

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Deep brain stimulation (DBS) is effective for Parkinson's disease (PD); however, its efficacy varies with genetic background, such as the GBA1 variant—the causative gene of Gaucher disease—associated with increased PD risk and cognitive decline after subthalamic nucleus (STN)‐DBS.
Hikaru Kamo, Genko Oyama, Mai Shimizu, Haruka Takeshige‐Amano, Takashi Ogawa, Wataru Sako, Noriko Nishikawa, Taku Hatano, Yuanzhe Li, Hiroyo Yoshino, Manabu Funayama, Masanobu Ito, Hirokazu Iwamuro, Atsushi Umemura, Nobutaka Hattori   +14 more
wiley   +1 more source

Dementia in Parkinson's Disease Correlates with α-Synuclein Pathology but Not with Cortical Astrogliosis

Parkinson's Disease, 2012
Dementia is a common feature in Parkinson’s disease (PD) and is considered to be the result of limbic and cortical Lewy bodies and/or Alzheimer changes.
Simone A. van den Berge, Josta T. Kevenaar, Jacqueline A. Sluijs, Elly M. Hol   +3 more
doaj   +1 more source

Basal Forebrain Volume and Concurrent Hallucinations and Mild Cognitive Impairment in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Visual hallucinations (VH) and mild cognitive impairment (MCI) often co‐occur in Parkinson's Disease (PD). Each symptom in isolation is associated with cholinergic basal forebrain (BF) atrophy. However, it is unclear whether BF integrity relates to one symptom preferentially or to their co‐occurrence, and whether this relationship ...
Sabrina M. Adamo, Vaishali Mutreja, Marta Statucka, Batu Kaya, Taylor W. Schmitz, Anthony C. Ruocco, Melanie Cohn   +6 more
wiley   +1 more source

Parkinson’s Disease and Dementia with Lewy Bodies: One and the Same

Journal of Parkinson’s Disease
The question whether Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) are expressions of the same underlying disease has been vigorously debated for decades.
Per Borghammer, Niels Okkels, Daniel Weintraub   +2 more
doaj   +1 more source

α-Synuclein pathology in post-mortem retina and optic nerve is specific for α-synucleinopathies

npj Parkinson's Disease, 2023
There is increasing interest in studying retinal biomarkers for various neurodegenerative diseases. Specific protein aggregates associated with neurodegenerative diseases are present in the retina and could be visualised in a non-invasive way. This study
Frederique J. Hart de Ruyter, Tjado H. J. Morrema, Jurre den Haan, Gina Gase, Jos W. R. Twisk, Johannes F. de Boer, Philip Scheltens, Femke H. Bouwman, Frank D. Verbraak, Annemieke J. M. Rozemuller, Jeroen J. M. Hoozemans   +10 more
doaj   +1 more source

Protein Aggregates and Polyglutamine Tracts In Neurodegenerative Disease [PDF]

, 2018
The incidence of neurodegenerative diseases such as Alzheimer\u27s Disease, Parkinson\u27s Disease, Huntington\u27s Disease and other Polyglutamine Diseases is projected to dramatically increase throughout the developed world, and yet the pathology of ...
Mack, John
core   +1 more source

Brain Imaging Changes Following Deep Brain Stimulation Patients with Parkinson's Disease: A Literature Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's Disease (PD) is a progressive neurodegenerative disorder primarily characterized by motor symptoms such as tremors, rigidity, and bradykinesia. Structural brain changes, including atrophy in the midbrain, basal ganglia, and cortical regions such as the frontal and temporal lobes, are observed in advanced stages.
Suraiya Mangra, Stanislaw Szlufik, Chao‐Kai Hu, Alexandre Boutet, Jürgen Germann, Andres M. Lozano   +5 more
wiley   +1 more source

An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias

Molecular Brain, 2017
Lewy body dementias are the second most common cause of neurodegenerative dementia in the elderly after Alzheimer’s disease (AD). The two clinical subgroups of Lewy body dementias, namely, dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (
Arnab Datta, Yuek Ling Chai, Jing Min Tan, Jasinda H. Lee, Paul T. Francis, Christopher P. Chen, Siu Kwan Sze, Mitchell K. P. Lai   +7 more
doaj   +1 more source